We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid POC Test Developed to Detect Influenza

By LabMedica International staff writers
Posted on 22 May 2017
Addressing the perennial threat of a major flu pandemic, researchers have developed fast, easy-to-use point-of-care (POC) diagnostic test for influenza that could head off rapid spread of the virus during an outbreak. More...
Preliminary clinical testing of the prototype device were encouraging.

Existing rapid diagnostic tests can help with diagnoses but require multiple processing steps that still need to be performed with lab equipment in specialized facilities. Prof. Paul Yager, University of Washington, and colleagues set out to create a simpler, low-cost device that overcomes these difficulties. The researchers incorporated multiple steps of influenza detection – viral lysis, target protein capture, labeling, rinsing, and an enzyme-driven color change – into one device. A user swabs the inside of a patient’s nose, inserts the swab into the device, and twirls it for 10 seconds to release the virus. The device takes care of the rest. After about 35 minutes (total test time from device initiation to result), it produces a visual readout that can be seen with the naked eye and recorded with a smartphone camera. The materials and reagents for one of these single-use disposable devices cost less than USA 6.

The test is based on a sandwich immunoassay for influenza virus nucleoprotein and runs in a 2-dimensional paper network format. The device contains all reagents and required no dedicated instruments.

The researchers trained clinical staff at Seattle Children’s Hospital to use the prototype device to detect influenza A and B in those specimens. 25 patients were tested during a flu outbreak. Influenza A was detected, with accuracy of ∼70% based on in-house qRT-PCR influenza A as a gold-standard comparison. The ratio of valid to total completed device runs yielded a success rate of 92%, and the negative predictive value for both the influenza A and B assay was 81%. The ability to diagnose respiratory infections rapidly and close to the patient was well received by hospital staff, inspiring further optimization of device function.

The study, by Huang S et al, was published April 26, 2017, in the journal Analytical Chemistry.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.